Estrella Immunopharma, Inc. held its Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026, via a virtual-only format. A quorum was established with approximately 70.5% of the outstanding shares of common stock represented. The primary proposal submitted to stockholders was the ratification of the appointment of Macias Gini & OConnell LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal to ratify the appointment of the independent auditor was approved by the stockholders.